Grass AllergyNCT01923779
ToleroMune Grass Follow on Study
An observational study of Grass Allergy and Rhinoconjunctivitis, run by Circassia Limited.
Trial summary
Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal allergy sufferers are allergic to grass pollen. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Grass Allergy, Rhinoconjunctivitis
- How many people
- 163 participants
- Where
- No sites listed yet
- Study dates
- May 2013to Sep 2013
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Subject previously randomised in study TG002 and completed all dosing visits and the PTC
Who may be able to join
- Previously randomised into study TG002, completed all treatment visits and PTC during calendar year 2012.
Who cannot join
- "Partly controlled" and "uncontrolled" asthma
- History of anaphylaxis to grass allergen
- FEV1 <80% of predicted.
- Treatment with beta-blockers, alpha-adrenoreceptor blockers, tranquilizers or psychoactive drugs
- Symptoms of a clinically relevant illness
- Subjects who cannot tolerate allergen challenge in the EEC
About this study
Official title: An Optional Follow-Up Study to Evaluate the Continued Efficacy of ToleroMune Grass in Grass Allergic Subjects Following Challenge With Grass Allergen in an Environmental Exposure Unit
Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal allergy sufferers are allergic to grass pollen. ToleroMune Grass is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of grass allergy.
The purpose of this optional observational follow-on study is to further evaluate rhinoconjunctivitis symptoms on exposure to Grass in the EEU among subjects who completed all dosing visits in study TG002 approximately one year after the start of treatment.
Read the detailed description
Subjects who completed all dosing visits and the post treatment challenge (PTC) in study TG002 will be invited to attend the Screening Visit for TG002a. Subjects will attend for 4 visits to the EEU on successive days. Following the last EEC visit a follow-up visit will be performed 3-10 days later.
- Conditions
- Grass Allergy, Rhinoconjunctivitis
- Keywords
- Grass allergy, Rhinoconjunctivitis, Environmental Exposure Unit, Immunotherapy, ToleroMune Grass
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| TG002 Subjects | Subjects previously randomised in study TG002 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total Rhinoconjunctivitis Symptom Score
Measured: Eighteen months post first dose in TG002
Secondary outcomes (7)
Symptom scores for nasal and non nasal symptoms
Measured: Eighteen months post first dose in TG002
Skin prick wheal diameter
Measured: Eighteen months post first dose in TG002
Peak Nasal Inspiratory Flow
Measured: Eighteen months post first dose in TG002
Grass specific IgA
Measured: Eighteen months post first dose in TG002
Grass specific IgE
Measured: Eighteen months post first dose in TG002
Grass specific IgG4
Measured: Eighteen months post first dose in TG002
Adverse Events
Measured: Eighteen months post first dose in TG002
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Aug 2013 (estimated)
- Study startMay 2013
- Primary completionAug 2013
- Study completionSep 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Grass AllergyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 163 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Circassia Limited
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Adiga Life Sciences, Inc., Pharm-Olam International
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01923779
- Sponsor's protocol ID
- TG002a
- Status last verified
- Nov 2013
- First submitted
- 16 Jul 2013
- Last updated
- 26 Nov 2013
- Results posted
- No
- Data monitoring committee
- No
Publications
Ellis AK, Frankish CW, Armstrong K, Steacy L, Tenn MW, Pawsey S, Hafner RP. Persistence of the clinical effect of grass allergen peptide immunotherapy after the second and third grass pollen seasons. J Allergy Clin Immunol. 2020 Feb;145(2):610-618.e9. doi: 10.1016/j.jaci.2019.09.010. Epub 2019 Sep 27.
PubMed 31568796
Study at a glance
From the registry record, last updated by the sponsor on 26 Nov 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Optional Follow-Up Study to Evaluate the Continued Efficacy of ToleroMune Grass in Grass Allergic Subjects Following Challenge With Grass Allergen in an Environmental Exposure Unit
- ClinicalTrials.gov ID
- NCT01923779
- Acronym / sponsor ID
- TG002a
- Conditions
- Grass Allergy, Rhinoconjunctivitis
- Keywords
- Grass allergy, Rhinoconjunctivitis, Environmental Exposure Unit, Immunotherapy, ToleroMune Grass
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 163 participants (estimated)
- Lead sponsor
- Circassia LimitedIndustry (pharma, biotech, devices)
- Collaborators
- Adiga Life Sciences, Inc., Pharm-Olam International
- Study start
- May 2013
- Primary completion
- Aug 2013 (actual)
- Study completion
- Sep 2013 (actual)
- First posted
- 16 Aug 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal allergy sufferers are allergic to grass pollen. ToleroMune Grass is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of grass allergy.
The purpose of this optional observational follow-on study is to further evaluate rhinoconjunctivitis symptoms on exposure to Grass in the EEU among subjects who completed all dosing visits in study TG002 approximately one year after the start of treatment.
Detailed description
Subjects who completed all dosing visits and the post treatment challenge (PTC) in study TG002 will be invited to attend the Screening Visit for TG002a. Subjects will attend for 4 visits to the EEU on successive days. Following the last EEC visit a follow-up visit will be performed 3-10 days later.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| TG002 Subjects | – | –Subjects previously randomised in study TG002 |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Subject previously randomised in study TG002 and completed all dosing visits and the PTC
Key inclusion criteria (1 listed)
- Previously randomised into study TG002, completed all treatment visits and PTC during calendar year 2012.
Key exclusion criteria (6 listed)
- "Partly controlled" and "uncontrolled" asthma
- History of anaphylaxis to grass allergen
- FEV1 <80% of predicted.
- Treatment with beta-blockers, alpha-adrenoreceptor blockers, tranquilizers or psychoactive drugs
- Symptoms of a clinically relevant illness
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Total Rhinoconjunctivitis Symptom Score
Time frame: Eighteen months post first dose in TG002
7 secondary outcomes
Symptom scores for nasal and non nasal symptoms
Time frame: Eighteen months post first dose in TG002
Skin prick wheal diameter
Time frame: Eighteen months post first dose in TG002
Peak Nasal Inspiratory Flow
Time frame: Eighteen months post first dose in TG002
Grass specific IgA
Time frame: Eighteen months post first dose in TG002
Grass specific IgE
Time frame: Eighteen months post first dose in TG002
Grass specific IgG4
Time frame: Eighteen months post first dose in TG002
Adverse Events
Time frame: Eighteen months post first dose in TG002
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Nov 2013.
- Derived from this study: PubMed 31568796Ellis AK, Frankish CW, Armstrong K, Steacy L, Tenn MW, Pawsey S, Hafner RP. Persistence of the clinical effect of grass allergen peptide immunotherapy after the second and third grass pollen seasons. J Allergy Clin Immunol. 2020 Feb;145(2):610-618.e9. doi: 10.1016/j.jaci.2019.09.010. Epub 2019 Sep 27.
Related trials for Grass Allergy
RecruitingObservational study
Investigating Nasal and Ocular Immune Response to Conjunctival Allergen Exposure
Allergic Rhinoconjunctivitis
Recruiting
Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study
Allergic Asthma, Thunderstorm Asthma
Recruiting
Evaluation of a Digital Tool to Improve Aeroallergen Immunotherapy Adherence. NavigAITme Project
Allergic Rhinitis
RecruitingObservational study
GRASS (Grass MATA MPL Real-world Assessment Study)
Grass Pollen Allergy
Active, not recruitingObservational study
Tyrosine Allergoid Paediatric and Adult Study
Allergic Rhinitis Due to Pollen, Allergic Conjunctivitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Grass Allergy and Rhinoconjunctivitis, run by Circassia Limited.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Nov 2013. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total Rhinoconjunctivitis Symptom Score (time frame: Eighteen months post first dose in TG002). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01923779, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Nov 2013.